Medivation Announces Presentation of Positive MDV3100 Clinical Data in - ForbesSAN FRANCISCO and CHICAGO, June 2 /PRNewswire-FirstCall/ — Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of the Company’s novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor Source: www.forbes.com



